Eli Lilly and Company (BVMF:LILY34)

Market Cap	4.90T
Revenue (ttm)	316.67B
Net Income (ttm)	98.13B
Shares Out	n/a
EPS (ttm)	108.94
PE Ratio	49.90
Forward PE	32.00
Dividend	0.75 (0.42%)
Ex-Dividend Date	Nov 13, 2025

Volume	16,824
Average Volume	20,593
Open	179.71
Previous Close	179.01
Day's Range	179.71 - 184.00
52-Week Range	113.00 - 208.36
Beta	0.39
RSI	56.09
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: LILY34

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD